Results 151 to 160 of about 5,762,549 (184)

Recurrent Temporal Bone Tenosynovial Giant Cell Tumor with Chondroid Metaplasia: The Use of Imaging to Assess Recurrence [PDF]

Neuroradiology Journal, 2014
Tenosynovial giant cell tumor (TGCT) is a benign proliferative lesion of unclear etiology. It is predominantly monoarticular and involves the synovium of the joint, tendon sheath, and bursa.
Peter M Som
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Clinical benefit of imatinib in patients with relapsed tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS).

Journal of Clinical Oncology, 2022
e23561 Background: TGCT/PVNS is an uncommon benign but locally aggressive tumor that affects joints and can lead to significant morbidity. It is characterized in most cases by a t(1;2) translocation that leads to overexpression of colony-stimulating factor 1 (CSF-1) and the accumulation of inflammatory cells that express CSF-1 receptor (CSF-1R) in ...
Jeanette Cu Yu, Manpreet Kaur Sidhu, Andrew Fang, Lee Jae Morse, Minggui Pan   +4 more
openaire   +1 more source

Clinical Characteristic and Surgical Treatment for the Spinal Tenosynovial Giant Cell Tumors (TGCT): Case Series and Literature Review

SN Comprehensive Clinical Medicine, 2020
Tenosynovial giant cell tumors are rare neoplasms of the tenosynovial tissue that can be either benign or malignant with locally aggressive characteristics. The morbidity in the axial skeletal system is extremely low, and past reports have been incomplete.
Jialin Li, Shaohui He, Kehan Xu, Jianru Xiao, Jing Chu   +4 more
openaire   +1 more source

Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study.

Journal of Clinical Oncology, 2015
10521 Background: Tenosynovial giant cell tumor (TGCT), a rare locally aggressive neoplasm of the synovium of joints and tendon sheaths, is associated with inflammation, pain and swelling in part d...
Heather Gelhorn, Sandra Tong, Grant Maclaine, John H. Healey, Susan V. Bukata, Vicki Leigh Keedy, Stephen Patrick Anthony, Andrew J Wagner, Daniel D. Von Hoff, Arun S. Singh, Carlos Becerra, Jennifer Hanlon, William Lenderking, Lindsey Murray, Henry H Hsu, Paul S. Lin, William D. Tap   +16 more
openaire   +1 more source

TENOSYNOVIAL GIANT CELL TUMOR (TGCT) OF HIP- A RARE CASE REPORT

INDIAN JOURNAL OF APPLIED RESEARCH
Tenosynovial giant cell tumor (TGCT) is a relatively rare inammatory disease that affects the joint synovium, bursae, and tendon sheaths, leading to nonspecic, often insidious discomfort in the joints. Surgery, with or without adjuvant radiation, is the primary therapy option for tenosynovial giant cell tumor.
Ambareesh P, Supreeth D R, Nishanth Reddy J, Vishwanath M S, Varun GBS, Shashank Sonth, Harish DV, Chandan Kumar RV, Nabhay G, Mahadeva HN   +9 more
openaire   +1 more source

Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors.

Journal of Clinical Oncology, 2012
10022 Background: Tenosynovial giant cell tumor (TGCT) is a rare, usually benign neoplasm of synovium and tendon sheath. TGCT is classified as localized or diffuse according to the extent of synovial involvement. Surgery is the primary treatment, but the recurrence rate is high, with possible multiple recurrences, joint function deterioration and ...
PALMERINI, EMANUELA, Pengo, S, Maki Robert G., Staals Eric L., Cioffi A, Alberghini M, Picci P, RUGGIERI, PIETRO, Mapelli S., Parafioriti A, Morris C, Gronchi A, Casali P. G, Ferrari S, Stacchiotti S.   +14 more
openaire   +3 more sources

Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

Journal of Clinical Oncology, 2010
10012 Background: PVNS/TGCT is a rare pathological entity affecting the synovium and tendon sheaths in young adults. This usually benign neoplasm is driven by overexpression of CSF1, in some cases as a result of a t(1;2) translocation which results in the fusion of the CSF1 gene to the COL6A3 promoter.
P. A. Cassier, S. Stacchiotti, H. Gelderblom, D. M. Thomas, W. Van Der Graaf, B. M. Seddon, D. Julien, A. J. Wagner, J. Blay   +8 more
openaire   +1 more source

Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).

Journal of Clinical Oncology, 2015
10561 Background: TGCT is a rare disease affecting the synovium and tendon sheaths of young adults.
Philippe Alexandre Cassier, Robert G. Maki, Andrew J. Wagner, Emmanuelle Bompas, Hans Gelderblom, Judith R. Kroep, David Morgan Thomas, Antoine Italiano, Beatrice M. Seddon, Winette T.A. Van Der Graaf, Julien Domont, Jean-Yves Blay, Silvia Stacchiotti   +12 more
openaire   +1 more source

Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.

Journal of Clinical Oncology, 2019
11042 Background: TGCT is a rare, locally aggressive neoplasm of the joint/tendon sheath linked to colony-stimulating factor 1 (CSF1) overexpression. Pexidartinib (pex), a selective inhibitor of CSF1 receptor, KIT, and FLT3-ITD, had a compelling tumor response rate in the TGCT cohort of a phase 1 study (NCT01004861) and significant tumor response vs ...
Hans Gelderblom, William D. Tap, Emanuela Palmerini, Silvia Stacchiotti, Zev A. Wainberg, Jayesh Desai, John H. Healey, Michiel van de Sande, Nicholas M. Bernthal, Charles Peterfy, Dale Edward Shuster, Qiang Wang, Henry Hsu, Andrew J. Wagner   +13 more
openaire   +1 more source

Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).

Journal of Clinical Oncology, 2018
11502Background: TGCT is a rare neoplasm of the joint/tendon sheath associated with colony-stimulating factor 1 (CSF-1) overexpression. No approved systemic therapy is available. Pexidartinib (Pex), a selective inhibitor of CSF-1 receptor, KIT, and FLT3-ITD, showed promising Phase 1 activity in TGCT.
Tap, William D., Gelderblom, Hans, Stacchiotti, Silvia, Palmerini, Emanuela, Ferrari, Stefano, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen N., Martin Broto, Javier, Ryan, Christopher W., Shuster, Dale Edward, Zhang, Ling, Wang, Qiang, Hsu, Henry, Lin, Paul S., Tong, Sandra, Wagner, Andrew J.   +18 more
openaire   +1 more source